Immune due to past infection

5-9 years
Protected by SIAs

1-4 years

5-9 years

1-4 years

Protected by routine vaccination with 2nd dose

15+ years

10-14 years

10-14 years

Immunization and
Susceptible

Protected by maternal antibodies

15+ years

Figure 10: Immunity against measles: Immunity profile by age

Table 8: Suspected sporadic and outbreak associated measles and rubella cases, 2010-2015

<table>
<thead>
<tr>
<th>Year</th>
<th>No. of suspected cases</th>
<th>No. of confirmed cases</th>
<th>No. of confirmed cases</th>
<th>No. of confirmed cases</th>
<th>No. of confirmed cases</th>
<th>No. of confirmed cases</th>
<th>No. of confirmed cases</th>
<th>No. of confirmed cases</th>
<th>No. of confirmed cases</th>
<th>No. of confirmed cases</th>
<th>No. of confirmed cases</th>
<th>No. of confirmed cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>10 185</td>
<td>97</td>
<td>98</td>
<td>98</td>
<td>98</td>
<td>98</td>
<td>98</td>
<td>98</td>
<td>98</td>
<td>98</td>
<td>98</td>
<td>98</td>
</tr>
<tr>
<td>2014</td>
<td>12 918</td>
<td>122</td>
<td>123</td>
<td>123</td>
<td>123</td>
<td>123</td>
<td>123</td>
<td>123</td>
<td>123</td>
<td>123</td>
<td>123</td>
<td>123</td>
</tr>
<tr>
<td>2013</td>
<td>66 949</td>
<td>264</td>
<td>265</td>
<td>265</td>
<td>265</td>
<td>265</td>
<td>265</td>
<td>265</td>
<td>265</td>
<td>265</td>
<td>265</td>
<td>265</td>
</tr>
<tr>
<td>2012</td>
<td>10 342</td>
<td>246</td>
<td>247</td>
<td>247</td>
<td>247</td>
<td>247</td>
<td>247</td>
<td>247</td>
<td>247</td>
<td>247</td>
<td>247</td>
<td>247</td>
</tr>
<tr>
<td>2011</td>
<td>11 940</td>
<td>285</td>
<td>286</td>
<td>286</td>
<td>286</td>
<td>286</td>
<td>286</td>
<td>286</td>
<td>286</td>
<td>286</td>
<td>286</td>
<td>286</td>
</tr>
</tbody>
</table>

For contact or feedback:
Expanded Program on Immunization
Ministry of Health, Jakarta, Indonesia
Tel: +62 21 6371094, Fax: +62 21 4244994
Email: epi@searo.who.int, www.searo.who.int/entity/immunization

Figure 14: Laboratory network

For More Information

Media Contact
Health Communication Branch
Communications, Knowledge Management and Media
WHO Regional Office for South-East Asia

Tel: +62 21 6371094, Fax: +62 21 4244994
Email: epi@searo.who.int, www.searo.who.int/entity/immunization

Immunization and Vaccine Development [2010]
WHO/SEAR/MEPI/2007

World Health Organization SEARO/FGL/IND • 31 August 2016

World Health Organization SEARO/FGL/IND • 31 August 2016
**EPI FACT SHEET**

**Figure 1:** National immunization coverage, 1990-2015

- **Figure 2:** DTP3 coverage, diphtheria and pertussis cases, 1990-2015

- **Table 3:** OPV supplementary immunization activities (SIA)
  - **Year** | **Activity** | **Age** | **Target** | **Population** | **Coverage (%)**
  - 2002 | Sub-national | 6-59 M | 14 916 018 | 592 930 |
  - 2003 | Sub-national | 6 M-12 Y | 2 672 376 | 912 106 |
  - 2004 | Sub-national | 6-12 Y | 2 180 918 |
  - 2005 | Sub-national | 6-12 Y | 2 978 096 |
  - 2006 | Sub-national | 6-12 Y | 6 665 950 |
  - 2007 | Sub-national | 1-3 Y | 11 203 018 |
  - 2008 | Sub-national | 6-12 Y | 2 072 918 |
  - 2009 | Sub-national | 6-12 Y | 2 072 918 |
  - 2010 | Sub-national | 9-59 M | 11 843 093 |
  - 2011 | Sub-national | 9-59 M | 11 843 093 |
  - 2012 | Sub-national | 9-59 M | 11 843 093 |
  - 2013 | Sub-national | 9-59 M | 11 843 093 |
  - 2014 | Sub-national | 9-59 M | 11 843 093 |

- 2015 | Sub-national | 9-59 M | 11 843 093 |

- **Table 4:** AFP surveillance performance indicators, 2006-2015
  - AFP cases | 10 123 | 9 835 | 9 621 | 9 324 | 9 064 | 8 806 | 8 538 | 8 260 | 8 030 | 7 838
  - Wild poliovirus confirmed cases | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1
  - Competence cases | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1
  - AFP rate | 2.48 | 2.52 | 2.75 | 2.83 | 2.62 | 2.75 | 2.76 | 2.74 | 2.45 | 2.04
  - Non-polio AFP rate | 2.48 | 2.52 | 2.75 | 2.83 | 2.62 | 2.75 | 2.76 | 2.74 | 2.45 | 2.04
  - Adequate stool specimens collection percentage | 92% | 92% | 92% | 92% |
  - Total stool samples collected | 24 070 028 |
  - % NPEV isolation | 12 |
  - % Time lapse of primary result reported | 100 |

- **Figure 3:** DTP-Hib-HepB3 coverage by province, 2015

- **Figure 4:** TT2 coverage and NT cases, 1980-2015

- **Table 5:** Reported cases of vaccine preventable diseases, 2005-2010
  - **Year** | **Disease** | **Type** | **Cases** | **Rate** |
  - 2005 | Polio | Paralytic | 142 | 225 |
  - 2006 | Polio | Paralytic | 207 | 40 |
  - 2007 | Polio | Paralytic | 226 |
  - 2008 | Polio | Paralytic | 269 |
  - 2009 | Polio | Paralytic | 198 |
  - 2010 | Polio | Paralytic | 167 |
  - 2011 | Polio | Paralytic | 238 |
  - 2012 | Polio | Paralytic | 207 |
  - 2013 | Polio | Paralytic | 137 |
  - 2014 | Polio | Paralytic | 157 |
  - 2015 | Polio | Paralytic | 167 |

- **Figure 5:** Non-polio AFP rate by province, 2015

- **Table 6:** MCV supplementary immunization activities
  - **Year** | **Activity** | **Coverage (%)**
  - 2006 | Sub-national | 92%
  - 2007 | Sub-national | 98%
  - 2008 | Sub-national | 95%
  - 2009 | Sub-national | 98%
  - 2010 | Sub-national | 98%
  - 2011 | Sub-national | 98%
  - 2012 | Sub-national | 98%
  - 2013 | Sub-national | 98%
  - 2014 | Sub-national | 98%
  - 2015 | Sub-national | 98%

- 2016 | Sub-national | 98%

- **Figure 6:** Adequate stool specimen collection percentage by province, 2015

- **Table 7:** Districts with more than 95% MCV1 coverage

- **Figure 7:** MCV1 & MCV2 coverage and measles cases, 1990-2015

- **Figure 8:** Sporadic and outbreak associated measles cases* by month and MRS SIA coverage, 2010-2015

- **Table 8:** MCV supplementary immunization activities

- **Table 9:** Non-polio AFP cases, 1990-2015

- **Figure 9:** Sporadic and outbreak associated measles cases* by month and MRS SIA coverage, 2010-2015
Table 4: AFP surveillance performance indicators, 2006–2015

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AFP cases</td>
<td>586</td>
<td>636</td>
<td>739</td>
<td>803</td>
<td>738</td>
<td>865</td>
<td>829</td>
<td>792</td>
<td>849</td>
<td>855</td>
</tr>
<tr>
<td>Wild poliovirus confirmed cases</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Completed cases</td>
<td>567</td>
<td>581</td>
<td>726</td>
<td>790</td>
<td>636</td>
<td>738</td>
<td>788</td>
<td>784</td>
<td>770</td>
<td>754</td>
</tr>
<tr>
<td>AFP rate</td>
<td>2.48</td>
<td>2.52</td>
<td>2.75</td>
<td>2.83</td>
<td>2.75</td>
<td>2.73</td>
<td>2.74</td>
<td>2.74</td>
<td>2.34</td>
<td>2.34</td>
</tr>
<tr>
<td>Non-polio AFP rate</td>
<td>2.48</td>
<td>2.52</td>
<td>2.75</td>
<td>2.83</td>
<td>2.75</td>
<td>2.73</td>
<td>2.74</td>
<td>2.74</td>
<td>2.34</td>
<td>2.34</td>
</tr>
</tbody>
</table>

Average number of AFP cases per 100,000 children under 15 years of age

Adequate stool specimen collection percentage (%)

- 2005-2007 result reported within 28 days
- 2008 onwards result reported within 14 days of sample received at laboratory

- 1 Number of discarded AFP cases per 100,000 children under 15 years of age

Table 5: Reported cases of vaccine preventable diseases, 2006–2015

<table>
<thead>
<tr>
<th>Year</th>
<th>Polio</th>
<th>Diphtheria</th>
<th>Pertussis</th>
<th>Neonatal Tetanus (NT)</th>
<th>Measles</th>
<th>Rubella</th>
<th>Mumps</th>
<th>Japanese Encephalitis</th>
<th>Congenital Rubella Syndrome</th>
<th>Spina Bifida</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>2</td>
<td>162</td>
<td>2305</td>
<td>118 (27%)</td>
<td>267 200</td>
<td>102</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2007</td>
<td>2</td>
<td>133</td>
<td>1328</td>
<td>141 (106%)</td>
<td>230 397</td>
<td>29</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2008</td>
<td>0</td>
<td>319</td>
<td>138 (100%)</td>
<td>230 397</td>
<td>29</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2009</td>
<td>0</td>
<td>158</td>
<td>872</td>
<td>123 (868)</td>
<td>28</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2010</td>
<td>0</td>
<td>432</td>
<td>ND</td>
<td>147 (100%)</td>
<td>166 332</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2011</td>
<td>0</td>
<td>506</td>
<td>114 (26%)</td>
<td>166 332</td>
<td>110 252</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2012</td>
<td>0</td>
<td>1130</td>
<td>ND</td>
<td>166 332</td>
<td>140 528</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2013</td>
<td>0</td>
<td>776</td>
<td>70 (55%)</td>
<td>140 528</td>
<td>136 415</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2014</td>
<td>0</td>
<td>1432</td>
<td>95 (72%)</td>
<td>136 415</td>
<td>216 030</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2015</td>
<td>0</td>
<td>250</td>
<td>120 (65%)</td>
<td>216 030</td>
<td>249 036</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

Source: WHO/UNICEF JRF

Figure 7: MCV1 & MCV2 coverage and measles cases, 1990–2015

Figure 8: MCV1 coverage by province, 2015

Figure 9: Sporadic and outbreak associated measles cases* by month and SIA coverage, 2010–2015

*Includes laboratory confirmed and epidemiologically linked cases
Source: WHO/UNICEF JRF report

Table 6: MCV supplementary immunization activities

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target population</th>
<th>Percentage</th>
<th>Number of districts</th>
<th>% of districts covered</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>Sub-national</td>
<td>9-59 M</td>
<td>1 763 122</td>
<td>97</td>
<td>2013</td>
<td>102</td>
</tr>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59 M</td>
<td>3 619 024</td>
<td>92</td>
<td>2013</td>
<td>102</td>
</tr>
<tr>
<td>2011</td>
<td>Sub-national</td>
<td>9-59 M</td>
<td>1 756 123</td>
<td>97</td>
<td>2013</td>
<td>102</td>
</tr>
<tr>
<td>2012</td>
<td>Sub-national</td>
<td>9-59 M</td>
<td>3 049 223</td>
<td>97</td>
<td>2013</td>
<td>102</td>
</tr>
<tr>
<td>2013</td>
<td>Sub-national</td>
<td>9-59 M</td>
<td>1 756 123</td>
<td>97</td>
<td>2013</td>
<td>102</td>
</tr>
<tr>
<td>2014</td>
<td>Sub-national</td>
<td>9-59 M</td>
<td>3 049 223</td>
<td>97</td>
<td>2013</td>
<td>102</td>
</tr>
<tr>
<td>2015</td>
<td>Sub-national</td>
<td>9-59 M</td>
<td>1 756 123</td>
<td>97</td>
<td>2013</td>
<td>102</td>
</tr>
</tbody>
</table>

Source: WHO/UNICEF JRF

Table 7: Districts with more than 95% MCV1 coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of districts</th>
<th>% of districts</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>97</td>
<td>100</td>
</tr>
<tr>
<td>2012</td>
<td>102</td>
<td>100</td>
</tr>
<tr>
<td>2013</td>
<td>102</td>
<td>100</td>
</tr>
<tr>
<td>2014</td>
<td>102</td>
<td>100</td>
</tr>
<tr>
<td>2015</td>
<td>102</td>
<td>100</td>
</tr>
</tbody>
</table>

Source: WHO/UNICEF JRF

Table 3: CPV supplementary immunization activities (SIA)

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Target population</th>
<th>Date</th>
<th>Date of 1st round coverage (%)</th>
<th>Date of 2nd round coverage (%)</th>
<th>1st round coverage (%)</th>
<th>2nd round coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>MCV1</td>
<td>6-59 M</td>
<td>Jan-06</td>
<td>95</td>
<td>Aug-06</td>
<td>98</td>
<td>98</td>
</tr>
<tr>
<td>2005</td>
<td>MCV1</td>
<td>6-59 M</td>
<td>Feb-06</td>
<td>95</td>
<td>Aug-06</td>
<td>98</td>
<td>98</td>
</tr>
<tr>
<td>2006</td>
<td>MCV1</td>
<td>6-59 M</td>
<td>Jan-07</td>
<td>95</td>
<td>Aug-07</td>
<td>98</td>
<td>98</td>
</tr>
<tr>
<td>2007</td>
<td>MCV1</td>
<td>6-59 M</td>
<td>Jan-08</td>
<td>95</td>
<td>Aug-08</td>
<td>98</td>
<td>98</td>
</tr>
<tr>
<td>2008</td>
<td>MCV1</td>
<td>6-59 M</td>
<td>Jan-09</td>
<td>95</td>
<td>Aug-09</td>
<td>98</td>
<td>98</td>
</tr>
<tr>
<td>2009</td>
<td>MCV2</td>
<td>6-59 M</td>
<td>Jan-10</td>
<td>92</td>
<td>Aug-10</td>
<td>97</td>
<td>97</td>
</tr>
<tr>
<td>2010</td>
<td>MCV2</td>
<td>6-59 M</td>
<td>Jan-11</td>
<td>97</td>
<td>Aug-11</td>
<td>97</td>
<td>97</td>
</tr>
<tr>
<td>2011</td>
<td>MCV2</td>
<td>6-59 M</td>
<td>Jan-12</td>
<td>97</td>
<td>Aug-12</td>
<td>97</td>
<td>97</td>
</tr>
<tr>
<td>2012</td>
<td>MCV2</td>
<td>6-59 M</td>
<td>Jan-13</td>
<td>97</td>
<td>Aug-13</td>
<td>97</td>
<td>97</td>
</tr>
<tr>
<td>2013</td>
<td>MCV2</td>
<td>6-59 M</td>
<td>Jan-14</td>
<td>97</td>
<td>Aug-14</td>
<td>97</td>
<td>97</td>
</tr>
<tr>
<td>2014</td>
<td>MCV2</td>
<td>6-59 M</td>
<td>Jan-15</td>
<td>97</td>
<td>Aug-15</td>
<td>97</td>
<td>97</td>
</tr>
<tr>
<td>2015</td>
<td>MCV2</td>
<td>6-59 M</td>
<td>Jan-16</td>
<td>97</td>
<td>Aug-16</td>
<td>97</td>
<td>97</td>
</tr>
<tr>
<td>2016</td>
<td>MCV2</td>
<td>6-59 M</td>
<td>Jan-17</td>
<td>97</td>
<td>Aug-17</td>
<td>97</td>
<td>97</td>
</tr>
</tbody>
</table>

Source: WHO/UNICEF JRF

Figure 5: MCV1 & MCV2 coverage by province, 2015

Figure 6: Adequate stool specimen collection percentage by province, 2015

Figure 4: T2O coverage and NT cases, 1980–2015

Indonesia achieved the maternal neonatal tetanus (MNT) elimination status in May 2016.
**EPI Fact Sheet**

**Figure 1: National immunization coverage, 1980-2015**

<table>
<thead>
<tr>
<th>Year</th>
<th>Act</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>NID</td>
<td>6-12</td>
<td>Y</td>
<td>93</td>
</tr>
<tr>
<td>2007</td>
<td>NID</td>
<td>13-15</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Figure 2: DTP3 coverage*, diphtheria and pertussis cases, 1990-2015**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>NID</td>
<td>6-12</td>
<td>Y</td>
<td>93</td>
</tr>
<tr>
<td>2007</td>
<td>NID</td>
<td>13-15</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Figure 3: MCV2 coverage**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
</tr>
</tbody>
</table>

**Figure 4: MCV1 & MCV2 coverage by province, 2015**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Table 4: AFP surveillance performance indicators, 2005-2015**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Figure 5: Non-polio AFP rate by province, 2015**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Table 5: Reported cases of vaccine preventable disease, 2005-2016**

<table>
<thead>
<tr>
<th>Year</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
</tr>
</tbody>
</table>

**Figure 6: Adequate stool specimen collection percentage by province, 2015**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Table 6: MCV supplementary immunization activities**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Figure 7: MCV1 & MCV2 coverage* and measles cases, 1990-2015**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Table 7: Districts with more than 95% MCV1 coverage**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Figure 8: MCV1 coverage by province, 2015**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Table 8: AFP surveillance performance indicators**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Figure 9: Sporadic and outbreak associated measles cases**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Table 9: CPV supplementary immunization activities (SIA)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Figure 10: OPV supplementary immunization activities (SIA)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Table 10: Reported cases of vaccine preventable disease, 2005-2016**

<table>
<thead>
<tr>
<th>Year</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
</tr>
</tbody>
</table>

**Figure 11: OPV surveillance performance indicators**

<table>
<thead>
<tr>
<th>Year</th>
<th>Activity</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
<td>92</td>
</tr>
</tbody>
</table>

**Table 12: Reported cases of vaccine preventable disease, 2005-2016**

<table>
<thead>
<tr>
<th>Year</th>
<th>Age</th>
<th>Target</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Sub-national</td>
<td>9-59</td>
<td>Y</td>
</tr>
</tbody>
</table>
Figure 10: Immunity against measles: immunity profile by age in 2015

Figure 11: Immunity against measles: immunity profile by age in 2016

Table 8: Suspended vaccines and Outreach and associated measles and rubella cases, 2010-2015

Table 9: Quality of test and laboratory surveillance for measles and rubella, 2012-2015

Table 10: Performance of Laboratory Surveillance, 2015

Table 11: Immunization system highlights

Table 12: Immunization schedule, 2016

Table 13: Basic information

Image 13: Laboratory network

Image 14: Laboratory network

Image 15: Laboratory network

Image 16: Laboratory network

Image 17: Laboratory network

Image 18: Laboratory network

Image 19: Laboratory network

Image 20: Laboratory network

Image 21: Laboratory network

Image 22: Laboratory network

Image 23: Laboratory network

Image 24: Laboratory network

Image 25: Laboratory network

Image 26: Laboratory network

Image 27: Laboratory network

Image 28: Laboratory network

Image 29: Laboratory network

Image 30: Laboratory network

Image 31: Laboratory network

Image 32: Laboratory network

Image 33: Laboratory network

Image 34: Laboratory network

Image 35: Laboratory network

Image 36: Laboratory network

Image 37: Laboratory network

Image 38: Laboratory network

Image 39: Laboratory network

Image 40: Laboratory network

Image 41: Laboratory network

Image 42: Laboratory network

Image 43: Laboratory network

Image 44: Laboratory network

Image 45: Laboratory network

Image 46: Laboratory network

Image 47: Laboratory network

Image 48: Laboratory network

Image 49: Laboratory network

Image 50: Laboratory network

Image 51: Laboratory network

Image 52: Laboratory network

Image 53: Laboratory network

Image 54: Laboratory network

Image 55: Laboratory network

Image 56: Laboratory network

Image 57: Laboratory network

Image 58: Laboratory network

Image 59: Laboratory network

Image 60: Laboratory network

Image 61: Laboratory network

Image 62: Laboratory network

Image 63: Laboratory network

Image 64: Laboratory network

Image 65: Laboratory network

Image 66: Laboratory network

Image 67: Laboratory network

Image 68: Laboratory network

Image 69: Laboratory network

Image 70: Laboratory network

Image 71: Laboratory network

Image 72: Laboratory network

Image 73: Laboratory network

Image 74: Laboratory network

Image 75: Laboratory network

Image 76: Laboratory network

Image 77: Laboratory network

Image 78: Laboratory network

Image 79: Laboratory network

Image 80: Laboratory network

Image 81: Laboratory network

Image 82: Laboratory network

Image 83: Laboratory network

Image 84: Laboratory network

Image 85: Laboratory network

Image 86: Laboratory network

Image 87: Laboratory network

Image 88: Laboratory network

Image 89: Laboratory network

Image 90: Laboratory network

Image 91: Laboratory network

Image 92: Laboratory network

Image 93: Laboratory network

Image 94: Laboratory network

Image 95: Laboratory network

Image 96: Laboratory network

Image 97: Laboratory network

Image 98: Laboratory network

Image 99: Laboratory network

Image 100: Laboratory network

Image 101: Laboratory network

Image 102: Laboratory network

Image 103: Laboratory network

Image 104: Laboratory network

Image 105: Laboratory network

Image 106: Laboratory network

Image 107: Laboratory network

Image 108: Laboratory network

Image 109: Laboratory network

Image 110: Laboratory network

Image 111: Laboratory network

Image 112: Laboratory network

Image 113: Laboratory network

Image 114: Laboratory network

Image 115: Laboratory network

Image 116: Laboratory network

Image 117: Laboratory network

Image 118: Laboratory network

Image 119: Laboratory network

Image 120: Laboratory network

Image 121: Laboratory network

Image 122: Laboratory network

Image 123: Laboratory network

Image 124: Laboratory network

Image 125: Laboratory network

Image 126: Laboratory network

Image 127: Laboratory network

Image 128: Laboratory network

Image 129: Laboratory network

Image 130: Laboratory network

Image 131: Laboratory network

Image 132: Laboratory network

Image 133: Laboratory network

Image 134: Laboratory network

Image 135: Laboratory network

Image 136: Laboratory network

Image 137: Laboratory network

Image 138: Laboratory network

Image 139: Laboratory network

Image 140: Laboratory network

Image 141: Laboratory network

Image 142: Laboratory network

Image 143: Laboratory network

Image 144: Laboratory network

Image 145: Laboratory network

Image 146: Laboratory network

Image 147: Laboratory network

Image 148: Laboratory network

Image 149: Laboratory network

Image 150: Laboratory network

Image 151: Laboratory network

Image 152: Laboratory network

Image 153: Laboratory network

Image 154: Laboratory network

Image 155: Laboratory network

Image 156: Laboratory network

Image 157: Laboratory network

Image 158: Laboratory network

Image 159: Laboratory network

Image 160: Laboratory network

Image 161: Laboratory network

Image 162: Laboratory network

Image 163: Laboratory network

Image 164: Laboratory network

Image 165: Laboratory network

Image 166: Laboratory network

Image 167: Laboratory network

Image 168: Laboratory network

Image 169: Laboratory network

Image 170: Laboratory network

Image 171: Laboratory network

Image 172: Laboratory network

Image 173: Laboratory network

Image 174: Laboratory network

Image 175: Laboratory network

Image 176: Laboratory network

Image 177: Laboratory network

Image 178: Laboratory network

Image 179: Laboratory network

Image 180: Laboratory network

Image 181: Laboratory network

Image 182: Laboratory network

Image 183: Laboratory network

Image 184: Laboratory network

Image 185: Laboratory network

Image 186: Laboratory network

Image 187: Laboratory network

Image 188: Laboratory network

Image 189: Laboratory network

Image 190: Laboratory network

Image 191: Laboratory network

Image 192: Laboratory network

Image 193: Laboratory network

Image 194: Laboratory network

Image 195: Laboratory network

Image 196: Laboratory network

Image 197: Laboratory network

Image 198: Laboratory network

Image 199: Laboratory network

Image 200: Laboratory network

Image 201: Laboratory network

Image 202: Laboratory network

Image 203: Laboratory network

Image 204: Laboratory network

Image 205: Laboratory network

Image 206: Laboratory network

Image 207: Laboratory network

Image 208: Laboratory network

Image 209: Laboratory network

Image 210: Laboratory network

Image 211: Laboratory network

Image 212: Laboratory network

Image 213: Laboratory network

Image 214: Laboratory network

Image 215: Laboratory network

Image 216: Laboratory network

Image 217: Laboratory network

Image 218: Laboratory network

Image 219: Laboratory network

Image 220: Laboratory network

Image 221: Laboratory network

Image 222: Laboratory network

Image 223: Laboratory network

Image 224: Laboratory network
Table 8: Suspected and confirmed cases of measles, rubella, 2010-2015

<table>
<thead>
<tr>
<th>Year</th>
<th>District/Province</th>
<th>Cases confirmed</th>
<th>Cases suspected</th>
<th>No. of confirm. %</th>
<th>No. of suspect %</th>
<th>No. of confirmed cases</th>
<th>No. of suspected cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>1879</td>
<td>267</td>
<td>267</td>
<td>100%</td>
<td>100%</td>
<td>267</td>
<td>267</td>
</tr>
<tr>
<td>2014</td>
<td>1905</td>
<td>250</td>
<td>250</td>
<td>100%</td>
<td>100%</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>2015</td>
<td>1905</td>
<td>250</td>
<td>250</td>
<td>100%</td>
<td>100%</td>
<td>250</td>
<td>250</td>
</tr>
</tbody>
</table>

Source: WHO Annual EPI Reporting Form.

Table 9: Quality of test and laboratory surveillance for measles and rubella, 2012-2015

<table>
<thead>
<tr>
<th>Year</th>
<th>Test (species)</th>
<th>Case classification (number)</th>
<th>Case classification (number)</th>
<th>Case classification (number)</th>
<th>Case classification (number)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>108</td>
<td>464</td>
<td>260</td>
<td>25</td>
<td>26</td>
</tr>
<tr>
<td>2014</td>
<td>118</td>
<td>474</td>
<td>290</td>
<td>29</td>
<td>30</td>
</tr>
<tr>
<td>2015</td>
<td>118</td>
<td>474</td>
<td>290</td>
<td>29</td>
<td>30</td>
</tr>
</tbody>
</table>

Source: WHO Annual EPI Reporting Form.

Table 10: Performance of Laboratory Surveillance, 2012-2015

<table>
<thead>
<tr>
<th>Year</th>
<th>Percent of population</th>
<th>Percent of population</th>
<th>Percent of population</th>
<th>Percent of population</th>
<th>Percent of population</th>
<th>Percent of population</th>
<th>Percent of population</th>
<th>Percent of population</th>
<th>Percent of population</th>
<th>Percent of population</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>30%</td>
<td>40%</td>
<td>50%</td>
<td>60%</td>
<td>70%</td>
<td>80%</td>
<td>90%</td>
<td>100%</td>
<td>110%</td>
<td>120%</td>
</tr>
<tr>
<td>2013</td>
<td>30%</td>
<td>40%</td>
<td>50%</td>
<td>60%</td>
<td>70%</td>
<td>80%</td>
<td>90%</td>
<td>100%</td>
<td>110%</td>
<td>120%</td>
</tr>
<tr>
<td>2014</td>
<td>30%</td>
<td>40%</td>
<td>50%</td>
<td>60%</td>
<td>70%</td>
<td>80%</td>
<td>90%</td>
<td>100%</td>
<td>110%</td>
<td>120%</td>
</tr>
</tbody>
</table>

Source: WHO Annual EPI Reporting Form.